VESALIO announces the successful initial use of its NeVa VS device in the United States for the treatment of post-aneurysmal subarachnoid hemorrhage (aSAH) cerebral vasospasm.
Vesalio hires Bob Bushok as VP of U.S. Sales and announces high first-pass rates and favorable safety profile in a 145-stroke patient data set for the NeVa™ thrombectomy device with findings published in the journal Interventional Neuroradiology.
MDR certification confirms the company’s commitment of ensuring that their innovative new products meet or exceed these rigorous new standards.
NeVa VS is a patented retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal rupture.
The first integrated clot micro-filtration technology for stroke thrombectomy patients.
Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round.
Vesalio announces the completion of enrollment in its FDA IDE clinical study for acute ischemic stroke.
As a board observer and senior advisor to the company, Earl Slee brings extensive medical device innovation and business development expertise.
As an independent board chairman, Mike Kujak will bring expert knowledge and know-how from his years of leadership in the medical device start-up space.
Vesalio announced the start of enrollment in its NATURE study using enVast™, the company’s first thrombectomy system for patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.